Market News & Trends
Pluristem’s Phase III Study Wins $8-Million Grant
Pluristem Therapeutics Inc. recently announced that its critical limb ischemia (CLI) program in the European Union has been awarded an $8-million grant. The grant is…
Amphivena Therapeutics Announces Acceptance of IND Application
Amphivena Therapeutics, Inc. recently announced that the US FDA has accepted an investigational new drug (IND) application for AMV564, the company’s proprietary T-cell redirecting bispecific…
Allergan Sales to Consolidate Four New Jersey Locations
The state Economic Development Authority approved Allergan's application for Grow NJ tax breaks that it said would keep 1,019 workers in the state, and add…
NIH Using PharmaJet in DNA Vaccine Clinical Trial
PharmaJet recently announced that the National Institutes of Health will use the PharmaJet Stratis needle-free device in a DNA vaccine clinical trial for the Zika…
OmniComm Systems Signs Multi-Million Dollar, 5-Year Agreement
OmniComm Systems, Inc. recently announced that one of the top five medical research universities in the US, selected OmniComm TrialMaster EDC and related services to…
Catalyst Biosciences Announces Agreement to Sell Three NNR Assets to Attenua
Catalyst Biosciences, Inc. recently announced it has entered into a definitive agreement to sell to Attenua, Inc. certain oral Neuronal Nicotinic Receptor (NNR) assets that…
Mayne Pharma Acquires Portfolio From Teva & Allergan
Mayne Pharma has recently completed its $652-million transaction with Teva and Allergan, taking ownership of 37 approved and five filed generic pharmaceutical products. This transaction…
Catalent Biologics & Zumutor Collaborate to Develop Antibodies With Enhanced ADCC Activity
Catalent Pharma Solutions and Zumutor Biologics Inc. recently announced a successful research study, combining Catalent’s proprietary GPEx technology and Zumutor’s fucose knockout platform, to create…
Abeona Therapeutics Uses Next-Generation AAV-Based Gene Therapy
Adeno-Associated Virus (AAV) vectors are currently among the most frequently used viral vectors for gene therapy. At recent meetings of the American Society for Gene…
Top Three Therapy Areas Account for 68% of Overall Pharmaceutical Industry Pipeline
The top three therapy areas – namely oncology, infectious diseases, and central nervous system (CNS) disorders – accounted for a combined 68% of the overall…
Top Three Therapy Areas Account for 68% of Overall Pharmaceutical Industry Pipeline
The top three therapy areas – namely oncology, infectious diseases, and central nervous system (CNS) disorders – accounted for a combined 68% of the overall…
Mayne Pharma Receives FDA Approval; Acquires Portfolio From Teva & Allergan
Mayne Pharma Inc. has received approval from the US FDA to market dofetilide capsules, a generic alternative to Tikosyn, an anti-arrhythmic agent used to treat…
MilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables
Allows for more precise control of release kinetics Enables development of drugs requiring fewer injections for enhanced patient comfort and compliance Billerica, Massachusetts, July 12,…
Mayne Pharma Receives FDA Approval; Acquires Portfolio From Teva & Allergan
Mayne Pharma Inc. has received approval from the US FDA to market dofetilide capsules, a generic alternative to Tikosyn, an anti-arrhythmic agent used to treat…
MilliporeSigma Expands Excipients Portfolio, Adding Polymers for Sustained Release Injectables
Allows for more precise control of release kinetics Enables development of drugs requiring fewer injections for enhanced patient comfort and compliance Billerica, Massachusetts, July 12,…
Biogen & AbbVie’s Once-Monthly ZINBRYTA Approved in European Union
The European Commission (EC) has granted marketing authorization for ZINBRYTA (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), Biogen…
Intrexon & ZIOPHARM Amend Exclusive Channel Collaborations
Intrexon Corporation and ZIOPHARM Oncology, Inc. recently announced amendments to their Exclusive Channel Collaborations (ECCs) in the fields of oncology and graft-versus-host-disease (GvHD) to improve…
Intra-Cellular Therapies Reports Completion of Enrollment of Phase III Clinical Trial
Intra-Cellular Therapies, Inc. recently announced completion of enrollment in the second Phase III clinical trial (ITI-007-302) of the company's lead product candidate ITI-007 for the…
ICON to Acquire Clinical Research Management
ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries, recently announced it has agreed, subject…
Owen Mumford Unveils New Self-Injection Pen
Owen Mumford, a global industry leader in medical device design and manufacturing, recently unveiled a new addition to its range of medical devices, Ovaleap Pen.…
